ARCT Arcturus Therapeutics Holdings Inc

Price (delayed)

$22.2

Market cap

$597.89M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.03

Enterprise value

$282.14M

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ ...

Highlights
Arcturus Therapeutics Holdings's debt has increased by 7% QoQ but it has decreased by 5% YoY
The net income has dropped by 196% year-on-year
The company's EPS has shrunk by 196% YoY

Key stats

What are the main financial stats of ARCT
Market
Shares outstanding
26.93M
Market cap
$597.89M
Enterprise value
$282.14M
Valuations
Price to book (P/B)
2.26
Price to sales (P/S)
4.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.27
Earnings
Revenue
$124.53M
EBIT
-$119.31M
EBITDA
-$116.03M
Free cash flow
$9.77M
Per share
EPS
-$4.03
Free cash flow per share
$0.36
Book value per share
$9.81
Revenue per share
$4.63
TBVPS
$15.58
Balance sheet
Total assets
$418.85M
Total liabilities
$154.88M
Debt
$27.65M
Equity
$263.97M
Working capital
$260.36M
Liquidity
Debt to equity
0.1
Current ratio
3.26
Quick ratio
3.21
Net debt/EBITDA
2.72
Margins
EBITDA margin
-93.2%
Gross margin
100%
Net margin
-86.2%
Operating margin
-99.1%
Efficiency
Return on assets
-24.7%
Return on equity
-38.7%
Return on invested capital
-644.9%
Return on capital employed
-39.3%
Return on sales
-95.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARCT stock price

How has the Arcturus Therapeutics Holdings stock price performed over time
Intraday
-0.8%
1 week
-5.21%
1 month
-15.49%
1 year
-39.01%
YTD
-29.59%
QTD
-8.83%

Financial performance

How have Arcturus Therapeutics Holdings's revenue and profit performed over time
Revenue
$124.53M
Gross profit
$124.53M
Operating income
-$123.37M
Net income
-$107.3M
Gross margin
100%
Net margin
-86.2%
The net income has dropped by 196% year-on-year
Arcturus Therapeutics Holdings's operating margin has shrunk by 111% QoQ
Arcturus Therapeutics Holdings's operating income has shrunk by 58% QoQ
The revenue has dropped by 56% year-on-year and by 25% since the previous quarter

Growth

What is Arcturus Therapeutics Holdings's growth rate over time

Valuation

What is Arcturus Therapeutics Holdings stock price valuation
P/E
N/A
P/B
2.26
P/S
4.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.27
The company's EPS has shrunk by 196% YoY
ARCT's P/B is 44% lower than its 5-year quarterly average of 4.1 and 21% lower than its last 4 quarters average of 2.9
ARCT's equity is down by 20% year-on-year and by 5% since the previous quarter
ARCT's price to sales (P/S) is 89% lower than its 5-year quarterly average of 43.1 but 10% higher than its last 4 quarters average of 4.4
The revenue has dropped by 56% year-on-year and by 25% since the previous quarter

Efficiency

How efficient is Arcturus Therapeutics Holdings business performance
The ROA has shrunk by 186% YoY
The company's return on equity has shrunk by 180% YoY

Dividends

What is ARCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARCT.

Financial health

How did Arcturus Therapeutics Holdings financials performed over time
Arcturus Therapeutics Holdings's total assets is 170% higher than its total liabilities
ARCT's current ratio is down by 31% QoQ and by 31% YoY
ARCT's quick ratio is down by 31% year-on-year and by 31% since the previous quarter
Arcturus Therapeutics Holdings's debt is 90% lower than its equity
ARCT's equity is down by 20% year-on-year and by 5% since the previous quarter
The debt to equity has increased by 11% from the previous quarter and by 11% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.